Update From the, Phase 2 RESTORE Trial of Elritercept in Patients With Myelofibrosis Receiving Ruxolitinib (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-832; Location: LEVEL 3, HALL B3; P2 | "Elritercept with ruxolitinib showed improvements in transfusion burden, spleen volume, platelet counts, and symptoms in patients with myelofibrosis, supporting further evaluation. GDF8/11: growth/differentiation factor 8/11, JAK: Janus kinase, JAK2: Janus kinase 2, MF-SAF-TSS: Myelofibrosis Symptom Assessment Form Total Symptom Score, RBC: red blood cell, TGF-β: tumor growth factor beta, VAF: variant allele frequency. Reused with permission."
Clinical • P2 data • Myelofibrosis • Oncology • ACVR2A • JAK2 • TGFB1
|
|
Ciro Rinaldi MD PhD 1; David M Ross 2; Lynette CY Chee 3; Alessandra Iurlo 4; Chun Huat Teh 5; Francesca Palandri 6; Maria Laura Fox 7; Jennifer O'Sullivan 8; Marco Brociner 9; Xin Tong 10; Varsha Sundaresan 10; Ziji Yu 10; Leopold Sellner 10; Katsuhiro Togami 10; Claire Harrison 8
|